Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT06127797
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Questionnaire/Interview — BEHAVIORALParticipation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
Study Details
To create a registry (database) of participants who come in for breast MRI scans. Researchers want to use this information to study if participants with dense breast tissue (tissue that is more difficult to see on mammogram).
Key Dates
- Start date
- Jan 11, 2024
- Status verified
- Feb 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2029
Study Design
- Enrollment
- 1,000 participants (estimated)
Arms
- Arm: Questionnaire/InterviewParticipants will take part in this study, before and after your routine breast MRI scan, participants will be asked to answer a series of questions about your experience with this MRI. It may take 10 to 20 minutes to answer. Participants may answer these questions in 1 of 3 ways: * In-person in the clinic with the study team (either through speaking or writing down your answers on a paper or electronic questionnaire form); * by phone at a later time; or * by paper or email at a later time.
Primary Outcome Measure
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year ]
Central Contacts
- Huong Le-Petross, MD713-563-7827
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | Huong Le-Petross, MD |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska